KPC(SH:600422)2016-04-28 16:00Financial Performance - Net profit attributable to shareholders rose by 16.11% to CNY 85,380,012.31 year-on-year[6] - Operating revenue grew by 13.14% to CNY 1,145,627,793.54 compared to the same period last year[6] - Basic and diluted earnings per share increased by 16.09% to CNY 0.2165[6] - Net profit for Q1 2016 reached CNY 85,938,778.49, representing a 12.3% increase from CNY 76,546,819.96 in Q1 2015[27] - The company's operating profit for Q1 2016 was CNY 99,607,785.97, up 21.4% from CNY 82,155,339.71 in Q1 2015[27] - Total operating revenue for Q1 2016 was CNY 310,812,744.35, an increase of 9.5% compared to CNY 284,425,217.95 in the same period last year[28] Assets and Liabilities - Total assets increased by 3.87% to CNY 5,140,009,403.15 compared to the end of the previous year[6] - The total assets as of March 31, 2016, amounted to CNY 3,904,424,162.56, compared to CNY 3,813,373,007.32 at the beginning of the year, reflecting a growth of 2.4%[24] - The company’s total liabilities increased to ¥1,269,329,580.37 from ¥1,163,232,538.35 at the beginning of the year[19] - The total liabilities increased to CNY 780,652,150.27 from CNY 748,842,249.85, marking a rise of 4.2%[24] Cash Flow - Cash flow from operating activities increased by 31.53% to CNY 59,974,255.06 year-on-year[6] - Net cash flow from operating activities increased by 32% to ¥59,974,255.06, attributed to higher sales receipts[14] - Cash inflow from investment activities was CNY 1,069,505,103.80, significantly higher than CNY 280,839,412.00 in the previous year[31] - Net cash flow from investment activities was negative CNY 239,376,328.26, worsening from negative CNY 66,885,094.18 in Q1 2015[31] - The net increase in cash and cash equivalents was $11,428,605.28, down from $88,466,887.25, reflecting a decrease of approximately 87.1%[33] Shareholder Information - The total number of shareholders reached 24,894 at the end of the reporting period[10] - The largest shareholder, Huafang Pharmaceutical Technology Co., Ltd., holds 29.79% of the shares, with 53,214,133 shares pledged[10] Investment and Expenses - Interest expenses increased by 54% to ¥8,846,521.17, primarily due to the accrual of long-term bond interest[14] - Investment income rose by 30% to ¥4,978,700.49, mainly driven by increased financial management income[14] - The company reported a 45% increase in income tax expenses to ¥16,744,860.70, reflecting higher profits[14] - The company reported a decrease in investment income to CNY 4,690,364.86 from CNY 43,748,368.37 in the previous year[28] Inventory and Retained Earnings - The company’s inventory increased to ¥650,142,718.67 from ¥616,045,395.64 at the beginning of the year[18] - The company reported an increase in retained earnings to CNY 588,045,631.24 from CNY 528,804,376.42, which is a growth of 11.2%[24] Future Plans - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[29]